A recent preclinical study has clearly shown that inhibition of NLRP3 by miRNA is able to block tumor growth and the immune-resistance of breast cancer through ASC/IL-1/IL-18 pathways; this inhibition provides new clinical insights for the therapy of breast cancer (103). This evidence concerns the gene IL18 and breast cancer.